New treatment options in mantle cell lymphoma
Mantle cell lymphoma has only recently been generally accepted as a distinct lymphoma entity. Hence, available clinical information is hampered by the lack of a uniformly accepted pathologic classification [11.1]. Furthermore, all series published so far are small, and mostly based on retrospective evaluations.
KeywordsEurope Lymphoma Leukemia Oncol Interferon
Unable to display preview. Download preview PDF.
- 2.Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995; 85:1075–82.PubMedGoogle Scholar
- 3.Wagner R, Press OW. Educational Booklet. Am Soc Hematol 1995:36–44.Google Scholar
- 14.Meusers P, Engelhard M, Bartels H et al. Mantle cell (centrocytic) lymphoma: long-term survival with advanced disease is possible. Blood 1996; 86 (Suppl 1): 53a.Google Scholar
- 15.Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non Hodgkin’s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995; 13: 2819–26.PubMedGoogle Scholar